FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?
US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.
You may also be interested in...
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.
Kennedy Jr. has been a long-time proponent of the view that vaccines are a cause of neurological diseases like autism, despite scientific research that has debunked those claims.
New claim puts the atypical antipsychotic on par with J&J's Risperdal.